Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.76 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.65 |
| ▸ | FLT3 | P36888 | 3/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | LTK | P29376 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.65 |
| ▸ | CDK8 | P49336 | 1/20 | 0.65 |
| ▸ | CDK7 | P50613 | 1/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.65 |
| ▸ | MST1R | Q04912 | 1/20 | 0.65 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.65 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448889 | 0.86 | MDM2 (1.00) | MDM2CSNK1A1FLT3NTRK1PRKD3 | |
| SCHEMBL6406354 | 0.86 | MDM2 (0.77) | MDM2CSNK1A1FLT3NTRK1PRKD3 | |
| SCHEMBL5469713 | 0.86 | MDM2 (1.00) | MDM2CSNK1A1FLT3NTRK1PRKD3 | |
| SCHEMBL5469718 | 0.86 | MDM2 (1.00) | MDM2CSNK1A1FLT3NTRK1PRKD3 | |
| SCHEMBL14448854 | 0.84 | MDM2 (0.81) | MDM2CSNK1A1FLT3NTRK1PRKD3 | |
| SCHEMBL5472670 | 0.84 | MDM2 (0.81) | MDM2CSNK1A1FLT3NTRK1PRKD3 | |
| SCHEMBL5472673 | 0.84 | MDM2 (0.81) | MDM2CSNK1A1FLT3NTRK1PRKD3 | |
| SCHEMBL5472209 | 0.83 | FLT3 (0.59) | MDM2CSNK1A1FLT3NTRK1PRKD3 | |
| SCHEMBL5472208 | 0.83 | FLT3 (0.59) | MDM2CSNK1A1FLT3NTRK1PRKD3 | |
| SCHEMBL14448904 | 0.83 | FLT3 (0.59) | MDM2CSNK1A1FLT3NTRK1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005044181-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-05-19 | — | — | WO | claimed |
| US-5834504-A | MODULATING, INHIBITING ABNORMAL CELL PROLIFERATION; ENZYME INHIBITION | SUGEN, INC. (US) | 1998-11-10 | — | — | US | claimed |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PFIZER INC | 2006-11-09 | — | — | US | disclosed |
| US-6906093-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097044-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | SUGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-6469032-B2 | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; ANTICARCINOGENIC, -DIABETIC, -PROLIFERATIVE AND -INFLAMMATORY AGENTS; VASCULAR SYSTEM DISORDERS | SUGEN, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020102608-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2002-08-01 | — | — | US | disclosed |
| US-20010027207-A1 | 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | TANG PENG CHO (US) | 2001-10-04 | — | — | US | disclosed |
| US-6225335-B1 | MODULATES TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; FOR THERAPY OF CANCER, ATHEROSCLEROSIS, ARTHRITIS AND RESTENOSIS AND METABOLIC DISEASES SUCH AS DIABETES | SUGEN, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0934931-A2 | 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators | Sugen, Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | disclosed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027207-A1 | 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | ERBB2, MKI67, ABL1 | MDM2 530/4885CSNK1A1 282/4885FLT3 246/4885 |
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | ERBB2, MKI67, ABL1 | MDM2 530/4885CSNK1A1 282/4885FLT3 246/4885 |
| US-20020102608-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | PTPRJ, ERBB2, JAK2 | MDM2 410/4885CSNK1A1 253/4885FLT3 250/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | MDM2 139/4885CSNK1A1 659/4885FLT3 3522/4885 |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGES3 | MDM2 157/4885CSNK1A1 752/4885FLT3 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.